Ibrutinib Treatment and EGFR-mutant Lung Adenocarcinoma

Isr Med Assoc J. 2021 Jun;23(6):385-386.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenine / administration & dosage
  • Adenine / adverse effects
  • Adenine / analogs & derivatives*
  • Adenocarcinoma of Lung / diagnosis*
  • Adenocarcinoma of Lung / genetics
  • Adenocarcinoma of Lung / pathology
  • Aged
  • ErbB Receptors / genetics
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Male
  • Neoplasms, Second Primary / diagnosis
  • Neoplasms, Second Primary / genetics
  • Neoplasms, Second Primary / pathology
  • Piperidines / administration & dosage*
  • Piperidines / adverse effects
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects

Substances

  • Piperidines
  • Protein Kinase Inhibitors
  • ibrutinib
  • EGFR protein, human
  • ErbB Receptors
  • Adenine